Execution of our strategy resulted in outstanding growth and strong value delivery 4Q2024 ING Group 6 February 2025 Delivering outstanding commercial growth across all business lines Note: all figures represent FY2024 figures, unless specifically mentioned 1) Includes private individuals only 2) Excluding RWAs in the Corporate Line 2 Mobile primary customers1) +1.1 mln Net core lending growth €+28 bln Net core deposits growth €+47 bln ▪ Very strong growth in mobile primary customers, all markets contributin ...

Presentation of RESULTS for the six months ended 31 December 2024 Niël Pretorius Chief Executive Officer Riaan Davel Chief Financial Officer Results for the six months ended 31 December 2024 / Page 2 DISCLAIMER Many factors could cause the actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward- looking statements, including, among others, adverse changes or uncertainties in general economic ...

Q4 Fiscal 2025 Earnings Results March 27, 2025 Braze Financial Highlights $642M QUARTERLY REVENUE RUN RATE 1 22% YoY REVENUE GROWTH 2,296 CUSTOMERS IN OVER 75 COUNTRIES DOLLAR-BASED NET RETENTION 111% RATE 96% SUBSCRIPTION REVENUE $17M GAAP NET LOSS Data as of January 31, 2025 or the three months ended, as applicable 1. Represents quarterly GAAP revenue multiplied by 4 2 Forward Looking Statements and Disclaimer Forward-Looking Statements This presentation contains, and statements made during this presentat ...

Q4 & YE 2024 Earnings Presentation March 27, 2025 TEN, Ltd. This presentation may contain forward-looking statements that are not based on historical fact, including without limitation, statements containing the words "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions. Because these forward-looking statements involve known and unknown risks and uncertainties, there are important factors that could cause actual results, events or developments to differ mate ...

Corporate Overview March 2025 NASDAQ: LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that ...

First Quarter 2025 Investor Conference Call March 27, 2025 ® 2025 H.B. Fuller Title Slide Disclosure Safe Harbor Statement Certain matters discussed today are forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements reflect our current expectations, and actual results may differ as they are subject to the kinds of risks that are enumerated ...

Full Year 2024 Business Update and Financial Results 27 March 2024 Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is in ...

NYSE American: BKTI Fourth Quarter & Full Year 2024 Earnings Results Thursday, March 27th, 2025 Safe Harbor Statement 2 This press release contains statements about future events and expectations which are "forward-looking statements" within the meaning of Sections 27A of the Securities Act of 1933, as amended, and 21E of the Exchange Act.. These forward-looking statements concern the Company's operations, economic performance, and financial condition, including, but not limited to the Company's long-term s ...

March 27, 2025 Fourth Quarter and Full Year 2024 Financial Results Welcome and Participants Dr. Jeffrey Graves President & Chief Executive Officer Jeffrey Creech Executive Vice President & Chief Financial Officer Mick McCloskey Vice President, Treasury & Investor Relations To participate via phone, please dial: 1-201-689-8345 3 Dr. Jeffrey Graves President & Chief Executive Officer 2 Forward Looking Statements Certain statements made in this presentation that are not statements of historical or current fact ...

Full Year 2024 Earnings and Business Update March 27, 2025 Disclaimer This presentation ("Presentation") does not contain or constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Alvotech (the "Company") to any person in the United States or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Any trademarks, servicemarks, trade names and copyrights of the Company and other companies contained in this Presentation are the p ...